Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces over €1.2 million public healthcare funding from two new multi-year public tender approvals in Italy for its groundbreaking acid reflux procedure, RefluxStop®.
The new public tender approvals were granted at the Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone” in Palermo and the Ospedale di Brunico (Azienda Sanitaria dell’Alto Adige) in South Tyrol. These strategic wins further solidify RefluxStop®’s growing acceptance within Italy’s national healthcare system and represent a significant step toward achieving broader product support, adoption, and a pathway to permanent reimbursement across Europe.
The clinical impact of RefluxStop® is already being realized in Italian hospitals. To date there are 12 RefluxStop® Centers of Excellence in the country. Prof. Antonino Agrusa, Associate Professor of Surgery at University of Palermo and leader of the surgical team at Policlinico “Paolo Giaccone” says, “Nearly a year post-procedure, our patients are experiencing remarkable success with no reflux and excellent swallowing function. This isn’t just an improvement; it’s a paradigm shift for Sicilian patients.”
Dr Günther Sitzmann, Head of the General Surgery Department at Ospedale di Brunico, added: “RefluxStop® allows patients to return to activities that GERD once made impossible. It is deeply rewarding to offer a solution to those who had given up on finding relief.”
Dr. Peter Forsell, CEO of Implantica and inventor of RefluxStop® said, “Governmental recognition of our device’s effectiveness and impact on patient lives is vital for patients who previously had limited treatment options. We sincerely thank Prof. Agrusa and Dr Sitzmann for their commitment and perseverance to help GERD patients get access to the best treatment option they well deserve. Securing public tenders are critical milestones to establish broader adoption and long-term permanent reimbursement. This momentum reinforces our mission to revolutionize GERD treatment for the over 12 million adult GERD sufferers in Italy and 1 billion sufferers around the world.
This information is from – https://www.implantica.com/
